The lead
Nasdaq Marketscompaniescorporate event
Novo Nordisk: STEP Young Phase 3 Trial With Semaglutide Shows Superior BMI Reduction At Week 68 (opens at Nasdaq Markets in a new tab)
Novo Nordisk announced first results from the STEP Young phase 3 trial of once-weekly semaglutide in children aged 6 to under 12 with obesity. The treatment combined with diet and physical activity showed superior BMI reduction at week 68.
Continue at Nasdaq Markets